Adult Dosing

• Not indicated in adults

Pediatric Dosing

Immunization(6 wks-7 yrs)

• Vaccination series consists of 5 doses administered as follows
• 0.5 mL IM x 3 at 2, 4, and 6 months of age at intervals of 4-8 wks (primary immunization)
• 0.5 mL IM at 15-18 months of age (booster dose)
• 0.5 mL IM at 4-6 yrs of age (booster dose)

• First dose may be given as early as 6 wks. Recommended interval between 3rd and 4th dose is 6-12 months; give 5th dose before kindergarten entry. 5th dose is not needed if 4th dose was given after 4th birthday

• For IM administration only. Not for intradermal, subcutaneous, IV, or intra-arterial administration. The preferred site is into the anterolateral aspect of the mid-thigh (vastus lateralis muscle) or into the deltoid muscle
• Booster shot every 10 years

[Outline]

• Adult Dosing
• Pediatric Dosing

• Active immunization of children, from 6 wks-7 yrs against diphtheria and tetanus in whom concomitant immunization against pertussis is not indicated

• Hypersensitivity to any of the ingredients of the product
• Hypersensitivity to thimerosal
• Acute febrile illness
• Outbreak of poliomyelitis

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

See Supplemental Patient Information

• Defer vaccination in acute illness unless benefit outweighs the risk
• If prior vaccine causes Guillain-Barré syndrome within 6 weeks, a decision should be made whether to give any tetanus toxoid-containing vaccine, based on careful consideration of the potential benefits and possible risks
• Patient’s immunization history should be reviewed for possible vaccine hypersensitivity prior to administering any vaccine. Epinephrine and other appropriate agents should be made available in case an anaphylactic or acute hypersensitivity reaction occurs
• The expected immune response will not be obtained if vaccine is administered to immunocompromised persons, or persons receiving immunosuppressive therapy
• DT vaccination may not protect all individuals
• Diphtheria, tetanus toxoid can cause hemorrhage when given to infants or children with coagulation disorder, including thrombocytopenia, or to those on anticoagulant therapy

Cautions: Use cautiously in

• Concurrent immunosuppressants
• Immunosuppressed patients
• Guillain-Barre syndrome within 6 wks of prior tetanus vaccine
• Coagulation disorder
• Anticoagulant use

Supplemental Patient Information

• Inform the parent or guardian of the benefits and risks of the vaccine and the importance of completing the immunization series

Pregnancy Category:C

Breastfeeding: Not applicable

• NEURO: Guillain-Barre syndrome, brachial neuritis, seizure
• GI: Loss of appetite, diarrhea, nausea
• LOCAL: Redness, pain, swelling, tenderness
• DERM: Erythema multiforme
• MISC: Fever, crying, anaphylactic reaction, generalized body pains, inflamed joints, muscle weakness

• Vaccine; induce neutralizing antibodies against toxins made by C.diphtheriae and C.tetani
• Metabolism: Other
• Excretion: Other
• Half-life: Unknown

US Trade Name(s)

• Only generic available

US Availability

diphtheria/tetanus toxoid (generic)

• INJ: 0.5 mL/vial

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Allergy & Immunology

Toxoids